Akari Therapeutics, Plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Akari Therapeutics, Plc (AKTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $6.46 per share as of 2024-06-30, per its 8-K filed 2024-09-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2024-09-06
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $6.46.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $5.28.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $5.36.
- 2022-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $0.02.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2024-06-30 | $6.46 8-K · filed 2024-09-06 |
| 2023-12-31 | $5.28 8-K · filed 2024-09-06 |
| 2022-12-31 | $5.36 8-K · filed 2024-09-06 |
| 2022-06-30 | $0.02 6-K · filed 2022-09-27 |
| 2021-12-31 | $0.07 6-K · filed 2022-09-27 |
| 2020-12-31 | $0.09 20-F · filed 2022-05-16 |
| 2019-12-31 | $0.10 20-F · filed 2022-05-16 |
| 2018-12-31 | $0.12 20-F · filed 2022-05-16 |
| 2017-12-31 | $0.15 20-F · filed 2021-04-21 |
| 2016-12-31 | $0.29 20-F · filed 2020-03-31 |
| 2015-12-31 | $0.34 20-F · filed 2019-04-23 |
| 2015-06-30 | $1.47 10-Q · filed 2015-08-12 |
| 2015-03-31 | $1.42 10-Q · filed 2015-05-12 |
| 2014-12-31 | $1.42 10-Q · filed 2015-08-12 |
| 2013-12-31 | $1.71 10-K · filed 2015-02-11 |
| 2012-12-31 | $1.44 10-K · filed 2015-02-11 |
| 2011-12-31 | $1.29 20-F · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |